推薦產品
等級
certified reference material
pharmaceutical secondary standard
品質等級
agency
traceable to USP 1012495
API 家族
beta-alanine
CofA
current certificate can be downloaded
技術
HPLC: suitable
gas chromatography (GC): suitable
mp
202 °C (dec.) (lit.)
應用
pharmaceutical (small molecule)
格式
neat
儲存溫度
2-30°C
SMILES 字串
NCCC(O)=O
InChI
1S/C3H7NO2/c4-2-1-3(5)6/h1-2,4H2,(H,5,6)
InChI 密鑰
UCMIRNVEIXFBKS-UHFFFAOYSA-N
尋找類似的產品? 前往 產品比較指南
相關類別
一般說明
用于质量控制的制药二级标准品,为制药实验室和制造商制备内部工作标准品提供了一种方便、高性价比的替代方案。β-丙氨酸是一种非蛋白质氨基酸,广泛存在于植物中,作为必需维生素泛酸盐的前体之一。它在微生物测定中表现出渗透保护剂的特性。它也是白花科植物中 β-丙氨酸甜菜碱的前体。
應用
这些二级标准品是合格的认证标准物质(CRM)。它们适用于多种分析应用,包括但不限于药物释放测试、药物的定性和定量分析方法开发、食品和饮料质量控制检测以及其他校准需求。
生化/生理作用
β丙氨酸是一种 β− 氨基酸,是泛酸的组分,是组氨酰基抗氧化剂二肽肌肽和鹅肌肽生物合成中的限速氨基酸。内源性 β-氨基酸,是甘氨酸受体的非选择性激动剂和G蛋白偶联孤儿受体TGR7(MrgD)的配体。 β-丙氨酸通量通过维持海洋生物、植入前小鼠胚胎和暴露于缺氧应激的哺乳动物细胞的渗透稳定性而发挥细胞保护作用。
分析報告
这些二级标准品可追溯至USP、EP(PhEur)和BP一级标准品。
其他說明
该认证标准物质(CRM)根据ISO 17034 和 ISO/IEC 17025进行生产和认证。有关此CRM使用的所有信息均可在检验报告上找到。
腳註
想要查看本品的检验报告示例,请在下框中输入LRAC3952。这只是一个示例证书,可能与您收到的批次不符。
儲存類別代碼
13 - Non Combustible Solids
水污染物質分類(WGK)
WGK 1
閃點(°F)
Not applicable
閃點(°C)
Not applicable
客戶也查看了
Physiology and Molecular Biology of Stress Tolerance in Plants (2006)
Neurochemistry international, 57(3), 177-188 (2010-06-15)
This review discusses the role of beta-alanine as a neurotransmitter. Beta-alanine is structurally intermediate between alpha-amino acid (glycine, glutamate) and gamma-amino acid (GABA) neurotransmitters. In general, beta-alanine satisfies a number of the prerequisite classical criteria for being a neurotransmitter: beta-alanine
The American journal of cardiology, 113(7), 1173-1177 (2014-02-12)
Dabigatran is a novel oral anticoagulant and may be useful during atrial fibrillation (AF) ablation for prevention of thromboembolic events. However, the benefits and adverse effects of periprocedural dabigatran therapy have not been thoroughly evaluated. A meta-analysis was performed to
The American journal of medicine, 127(7), 650-656 (2014-02-18)
The bleeding risk among patients with atrial fibrillation is higher early after initiating therapy with vitamin K antagonists (VKAs). Evidence is limited on how prior VKA experience affects bleeding risk when initiating novel oral anticoagulant therapy. We investigated this among
The Canadian journal of cardiology, 30(8), 888-897 (2014-07-30)
Recent reports suggest altered antithrombotic efficacy and higher risk of bleeding with new oral anticoagulants (NOACs) in patients with renal insufficiency. A meta-analysis was performed to evaluate the efficacy and safety with recommended doses of NOAC compared with conventional treatment
我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務